Floatz logo

LYSINE

Neuroendocrine Tumors

David BushnellSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Surufatinib
Shanghai Changzheng Hospital
Phase 3BB
Oxodotreotide
Fundación de investigación HM
Phase 3BB

View all 50 →

Same molecule, other indications

LYSINE is also rated in:

major depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
NETsDormant
CC
Indicative ·
46 / 100
View asset →
Metastatic Neuroendocrine Prostate CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →